New ChemoMetec CEO: ”You have to prioritize”
ChemoMetec's newly-appointed CEO, Torsten Freltoft, says he is thoroughly committed to creating growth on the all-important US market – but not at any cost.
by Benjamin Werner Christensen
Top chief, Torsten Freltoft, hopes his company ChemoMetec will truly find its footing on the lucrative US market, but it neither can nor will happen overnight. The increased focus on the US market already started to pay off in the past fiscal year, and that development should continue in coming years.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
ChemoMetec launches new cell count device
For abonnenter
Chemometec loses turnover
For abonnenter
Millions in deficit for Danish medtech company
For abonnenter
